背景:先前的一项探索性研究证明了Lab4益生菌缓解IBS症状的能力,和事后数据分析表明女性亚组的改善最大。这项研究的目的是确认这种多菌株益生菌对女性IBS症状严重程度的影响。
方法:8周,单中心,随机化,双盲,安慰剂对照,在70名罗马IV诊断为肠易激综合征(IBS)的女性中,每天接受Lab4益生菌(250亿个菌落形成单位)或匹配的安慰剂。IBS症状严重程度评分(IBS-SSS)相对于基线的变化,日常排便习惯,焦虑,抑郁症,与IBS相关的控制,和回避行为,执行功能,和粪便微生物组成进行了评估。该研究前瞻性注册:ISRCTN14866272(注册日期20/07/22)。
结果:在研究结束时,IBS-SSS在组间有显著降低(-85.0,p<0.0001),焦虑和抑郁评分(分别为-1.9,p=0.0002和-2.4,p<0.0001),以及与IBS相关的控制和回避行为得分(-7.5,p=0.0002),都有利于益生菌组。益生菌组中较高比例的参与者具有正常的粪便形式(p=0.0106)和/或较少的排便具有松散的粪便形式(p=0.0311)。对粪便微生物群的整体多样性影响不大,但在罗斯布里亚有显著差异,Holdemanella,Blautia,不动杆菌属,Ruminococus,普雷沃氏菌,拟杆菌,研究结束时,益生菌组和安慰剂组之间的厌氧菌。
结论:每日补充这种益生菌可能是IBS管理中考虑的一种选择。
BACKGROUND: A previous exploratory
study demonstrated the ability of the Lab4 probiotic to alleviate the symptoms of IBS, and post hoc data analysis indicated greatest improvements in the female subgroup. The aim of this
study is to confirm the impact of this multistrain probiotic on
IBS symptom severity in females.
METHODS: An 8-week, single-center, randomized, double-blinded, placebo-controlled, superiority study in 70 females with Rome IV-diagnosed irritable bowel syndrome (IBS) receiving the Lab4 probiotic (25 billion colony-forming units) daily or a matched placebo. Changes from baseline in the
IBS-symptom severity score (
IBS-SSS), daily bowel habits, anxiety, depression, IBS-related control, and avoidance behavior, executive function, and the fecal microbiota composition were assessed. The
study was prospectively registered: ISRCTN 14866272 (registration date 20/07/22).
RESULTS: At the end of the
study, there were significant between-group reductions in
IBS-SSS (-85.0, p < 0.0001), anxiety and depression scores (-1.9, p = 0.0002 and -2.4, p < 0.0001, respectively), and the IBS-related control and avoidance behavior score (-7.5, p = 0.0002), all favoring the probiotic group. A higher proportion of the participants in the probiotic group had normal stool form (p = 0.0106) and/or fewer defecations with loose stool form (p = 0.0311). There was little impact on the overall diversity of the fecal microbiota but there were significant differences in Roseburia, Holdemanella, Blautia, Agathobacter, Ruminococcus, Prevotella, Bacteroides, and Anaerostipes between the probiotic and placebo groups at the end of the study.
CONCLUSIONS: Daily supplementation with this probiotic may represent an option to be considered in the management of IBS.